Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Invirase (saquinavir) protease inhibitor gains full approval Sept. 27.

Executive Summary

ROCHE INVIRASE/HIVID COMBINATION REDUCES MORTALITY RISK BY 68% and risk of progression to first AIDS- defining event or death by 49% compared to saquinavir or zalcitabine (ddC) alone, according to data from a 940-patient Phase III clinical endpoint trial included in new labeling for the protease inhibitor. Saquinavir mesylate gained full approval Sept. 27 by FDA for use "in combination with nucleoside analogs...for the treatment of HIV infection."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS028978

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel